Concentration of nitric oxide products in bronchoalveolar fluid obtained from infants who develop chronic lung disease of prematurity

Vyas, Julian R.; Currie, Andrew E.; Shuker, David E. G.; Field, David J.; Kotecha, Sailesh
November 1999
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Nov1999, pF217
Academic Journal
No abstract available.


Related Articles

  • Serum bilirubin and development of chronic lung disease in very low birth weight infants. Schrod, L.; von Stockhausen, H.-B. // European Journal of Pediatrics;1999, Vol. 158 Issue 2, p169 

    Evaluates bilirubin concentrations in premature infants with low birth weights to examine the correlation of oxidative stress markers in tracheobronchial aspirates and the development of chronic lung disease. Role of oxidative injury in the pathogenesis of chronic lung disease; ion on the Total...

  • Decreased neutrophil apoptosis in tracheal fluids of preterm infants at risk of chronic lung disease. Oei, J.; Liu, K.; Wang, H.; Henry, R. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;May2003, Vol. 88 Issue 3, p245 

    Reports on a study by researchers from Australia, which concludes that preterm infants with low levels of IL10 and neutrophil apoptosis may be predisposed to disordered lung repair. Examination of both reduced neutrophil apoptosis and IL10 in the tracheal fluid of premature infants who...

  • Ascorbate acid concentration in airways lining fluid from infants who develop chronic lung disease of prematurity. Vyas, Julian R.; Currie, Andrew; Dunster, Chrissie; Kelly, Frank J.; Kotecha, Sailesh // European Journal of Pediatrics;2001, Vol. 160 Issue 3, p177 

    Abstract Chronic lung disease of prematurity (CLD) remains a common cause of morbidity and mortality in preterm infants. Oxygen toxicity remains a major risk factor for the development of CLD and as a consequence the antioxidant status of CLD babies is a major focus of interest. In the present...

  • Neurodevelopmental Outcomes of Premature Infants Treated with Inhaled Nitric Oxide. Mestan, Karen K.L.; Marks, Jeremy D.; Hecox, Kurt; Huo, Dezheng; Schreiber, Michael D. // New England Journal of Medicine;7/7/2005, Vol. 353 Issue 1, p23 

    Background: Chronic lung disease and severe intraventricular hemorrhage or periventricular leukomalacia in premature infants are associated with abnormal neurodevelopmental outcomes. In a previous randomized, controlled, single-center trial of premature infants with the respiratory distress...

  • Inhaled Nitric Oxide in Premature Infants with the Respiratory Distress Syndrome. Schreiber, Michael D.; Gin-Mestan, Karen; Marks, Jeremy D.; Huo, Dezheng; Lee, Grace; Srisuparp, Pimol // New England Journal of Medicine;11/27/2003, Vol. 349 Issue 22, p2099 

    Background: Inhaled nitric oxide improves gas exchange, decreases pulmonary vascular lability, and reduces pulmonary inflammation. We hypothesized that the use of inhaled nitric oxide would decrease the incidence of chronic lung disease and death in premature infants with the respiratory...

  • Exhaled Breath Condensates as a Source for Biomarkers for Characterization of Inflammatory Lung Diseases. Bajaj, Puneet; Ishmael, Faoud T. // Journal of Analytical Sciences, Methods & Instrumentation;Mar2013, Vol. 3 Issue 1, p17 

    Inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease are common and difficult to diagnose and characterize. This is due in large part to difficulty in obtaining samples directly from the inflamed lung. The collection of lung secretions by traditional methods...

  • Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. Radicioni, Maurizio; Bruni, Alessia; Camerini, Piergiorgio // European Journal of Pediatrics;Aug2011, Vol. 170 Issue 8, p1075 

    Premature infants with preterm premature rupture of membranes (PPROM) are at high risk of severe respiratory failure because of lung hypodysplasia associated with persistent pulmonary hypertension of the newborn (PPHN). We describe the clinical course of a 28-week gestation infant with PPROM...

  • NO therapy holds great promise for tiniest preemies. Asch-Goodkin, Judith // Contemporary Pediatrics;Sep2006, Vol. 23 Issue 9, p17 

    The article focuses on the findings of multicenter clinical studies regarding the treatment with inhaled nitric oxide to prevent chronic lung disease in some very-low birth-weight premature infants. The studies involved infants treated at 37 medical centers which were born at less than 34 weeks'...

  • Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease? Harrison, C. M.; Andersen, C. C. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2005, Vol. 90 Issue 1, pF6 

    Neonatal chronic lung disease is a common problem for surviving infants of extreme prematurity. Although the precise pathophysiology is still not known, it is clear that inflammation provides a common link that amplifies the injury to the premature lung. Current invasive measures of pulmonary...

  • Thalidomide Reduces Lipopolysaccharide/Zymosan-Induced Acute Lung Injury in Rats. Chien-Sheng Chen; Wann-Cherng Perng; Chien-Wen Chen; Kun-Lun Huang; Chin-Pyng Wu; Mao-Hsiung Yen // Journal of Biomedical Science;Sep/Oct2004, Vol. 11 Issue 5, p591 

    Pharmacological therapies targeting fulminant lung inflammation in acute lung injury (ALI) need to be improved. We evaluated the effect of thalidomide, a chemical modulating both acute and chronic inflammation, on ALI induced by intravenous administration of lipopolysaccharide (LPS) and zymosan...


Read the Article


Sign out of this library

Other Topics